| アブストラクト | AIMS: To determine whether enzyme-inducing antiseizure drugs (ASDs) affect the risk of developing chronic obstructive pulmonary disease (COPD) or lung cancer in smokers. METHODS: Cases of COPD and lung cancer and matched controls without these conditions were identified from a population of smokers with >/=1 prescription for any type of ASD in the Clinical Practice Research Datalink UK database of patients managed in primary care (1995-2016). A matched case-control study was performed utilising multivariate logistic regression analyses of exposure to enzyme-inducing ASDs compared to non-enzyme-inducing ASDs. The duration of ASD exposure and level of tobacco exposure were also assessed. RESULTS: We identified 5952 incident COPD and 1373 incident lung cancer cases, and 59 328 and 13 681 matched controls, respectively. Compared with never use, ever use of enzyme-inducing ASDs was associated with slightly decreased risk estimates of COPD (adjusted odds ratio: 0.85, 95% confidence interval: 0.81-0.89) and lung cancer (adjusted odds ratio: 0.82, 95% confidence interval: 0.73-0.92). These risk estimates were attenuated in heavy smokers. CONCLUSION: We found slightly decreased risk estimates of COPD and lung cancer among smokers taking enzyme-inducing ASDs and hypothesise that this may be related to induction of detoxification of tobacco-specific lung toxins. |
|---|
| ジャーナル名 | British journal of clinical pharmacology |
|---|
| 投稿日 | 2020/8/2 |
|---|
| 投稿者 | Leuppi-Taegtmeyer, Anne B; Reinau, Daphne; Yilmaz, Stella; Ruegg, Stephan; Krahenbuhl, Stephan; Jick, Susan S; Leuppi, Jorg D; Meier, Christoph R |
|---|
| 組織名 | Department of Clinical Pharmacology & Toxicology, University Hospital Basel,;Switzerland.;University of Basel, Switzerland.;Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,;Department of Pharmaceutical Sciences, University of Basel, Switzerland.;Hospital Pharmacy, University Hospital Basel, Switzerland.;Department of Neurology, University Hospital Basel, Switzerland.;Boston Collaborative Drug Surveillance Program, Lexington, MA, USA.;Boston University School of Public Health, Lexington, MA, USA.;Medical University Clinic, Cantonal Hospital Baselland, Liestal, Switzerland. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32738070/ |
|---|
